Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):377-8. doi: 10.1097/01.qai.0000176591.06549.de.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Anti-Infective Agents / administration & dosage*
  • Anti-Retroviral Agents / administration & dosage
  • Antiprotozoal Agents / administration & dosage
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Dapsone / administration & dosage
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy*
  • Humans
  • India
  • Male
  • Pentamidine / administration & dosage
  • Pneumonia, Pneumocystis / complications
  • Pneumonia, Pneumocystis / immunology
  • Pneumonia, Pneumocystis / prevention & control*
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage
  • Withholding Treatment*

Substances

  • Anti-Infective Agents
  • Anti-Retroviral Agents
  • Antiprotozoal Agents
  • Pentamidine
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Dapsone